nutlin-3a mdm2 inhibitor nutlin-3, (-)- nutlin3a
Nutlin-3a | ≥99%(HPLC) | Selleck | Mdm2 inhibitor
Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner. Features Highly selective MDM2 inhibitor with a much
Nutlin-3a ≥98% (HPLC) | (-)-Nutlin-3 | Sigma-Aldrich
Nutlin-3a [(-)-Nutlin] is a more potent diastereoisomer of racemic MDM2 antagonist Nutlin-3. It was called enantiomer-a since it elutes as the first peak from chiral purification of racemic nutlin-3. Nutlin-3a is a potent inhibitor of MDM2 (mous
MDM2 Inhibitor Nutlin-3a Induces Apoptosis and Senescence in Cutaneous T-Cell Lymphoma: Role of p53
P53 is rarely mutated in cutaneous T-cell lymphoma (CTCL) and is therefore a promising target for innovative therapeutic approaches. Nutlin-3a is an inhibitor of MDM2 (human homolog of murine double minute 2), which disrupts its interaction with
Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells
Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells Leukemia. 2009 Nov;23(11):2090-101. doi: 10.1038/leu.2009.171. Epub 2009 Aug 27
Nutlin 3 - an overview | ScienceDirect Topics
5.2.21 Nutlin-3 Nutlin-3 is a specific MDM2 inhibitor, which blocks the p53-binding domain of MDM2 resulting in p53 stabilization and p53 activation (Arkin and Wells, 2004; Chene, 2004a,b; Dudkina and Lindsley, 2007; Fotouhi and Graves, 2005;
The hydrophobically-tagged MDM2–p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a - Chemical
Nutlin-3a-HT, created by fusing the hydrophobic tag HyT13 to the MDM2–p53 interaction inhibitor Nutlin-3a, prevented cellular accumulation of MDM2 upon p53 reactivation, and had a stronger effect on cell viability and the induction of apoptosis
MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
6/10/2015 · MDM2 (mouse double minute 2) inhibitors that activate p53 and induce apoptosis in a non-genotoxic manner are in clinical development for treatment of leukemias. P53 can modulate other programmed cell death pathways including autophagy both
Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
6/8/2015 · The MDM2 inhibitor Nutlin-3a was purchased from Selleck Chemicals (Houston, TX). Cell lines were incubated in a humidified atmosphere at 37°C with 5% CO 2 and cultured in RPMI 1640 media supplemented with 10% fetal bovine serum, 100 U/ml
Activation of the p53 Pathway by the MDM2 Inhibitor nutlin-3a Overcomes BCL2 Overexpression in a Preclinical Model of Diffuse Large B-cell
Nutlin-3a induces cell cycle arrest and/or cell death in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21) through activation of the p53 pathway. (a) At 24 h after treatment with 2 μ nutlin-3a in DLBCL cell lines with
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant
15/12/2011 · Nutlin-3 was shown to induce and/or promote DNA damage. 3, 4 Moreover, we show that the numbers of genes significantly differentially expressed (P<0.05 after correction for multiple testing
Nutlin - Wikipedia
Nutlins are cis-imidazoline analogs which inhibit the interaction between mdm2 and tumor suppressor p53, and which were discovered by screening a chemical library by Vassilev et al. Nutlin-1, nutlin-2, and nutlin-3 were all identified in the
MDM2 Inhibitor Nutlin-3a Induces Apoptosis and Senescence in Cutaneous T-Cell Lymphoma: Role of p53
MDM2 Inhibitor Nutlin-3a Induces Apoptosis and Senescence in Cutaneous T-Cell Lymphoma: Role of p53 Valentina Manfe´1, Edyta Biskup1, Peter Johansen2, Maria R. Kamstrup1, Thorbjørn F. Krejsgaard3, Niels Morling2,4, Hans C. Wulf1 and Robert